The scientist’s investigation covers issues in Microbiology, Multilocus sequence typing, Antibiotics, Molecular epidemiology and Escherichia coli. The Microbiology study combines topics in areas such as Enterobacteriaceae and Virology. His research investigates the link between Enterobacteriaceae and topics such as Fosfomycin that cross with problems in Antibacterial agent and Serotype.
While the research belongs to areas of Multilocus sequence typing, Jesús Oteo spends his time largely on the problem of Klebsiella pneumoniae, intersecting his research to questions surrounding Meropenem. His work focuses on many connections between Molecular epidemiology and other disciplines, such as Pulsed-field gel electrophoresis, that overlap with his field of interest in Plasmid, Polymerase chain reaction and Ertapenem. Jesús Oteo works mostly in the field of Escherichia coli, limiting it down to concerns involving Drug resistance and, occasionally, Outbreak and Infection control.
His primary areas of investigation include Microbiology, Escherichia coli, Klebsiella pneumoniae, Antibiotic resistance and Multilocus sequence typing. His Microbiology research is multidisciplinary, incorporating elements of Molecular epidemiology and Enterobacteriaceae. His studies deal with areas such as AMOXICILLIN/CLAVULANATE and Virulence as well as Escherichia coli.
His work carried out in the field of Klebsiella pneumoniae brings together such families of science as Colistin, Colonisation and Outbreak. His Antibiotic resistance study incorporates themes from Erythromycin, Ciprofloxacin, Ampicillin and Antimicrobial. In his research on the topic of Multilocus sequence typing, Ceftazidime is strongly related with Meropenem.
Microbiology, Klebsiella pneumoniae, Escherichia coli, Enterobacteriaceae and Carbapenem are his primary areas of study. His work deals with themes such as Gene and Multilocus sequence typing, which intersect with Microbiology. The concepts of his Klebsiella pneumoniae study are interwoven with issues in Antibiotics, Internal medicine, Epidemiology, Molecular epidemiology and Pediatrics.
His studies examine the connections between Escherichia coli and genetics, as well as such issues in Drug resistance, with regards to Carbapenemase-Producing Enterobacteriaceae. His Enterobacteriaceae study combines topics from a wide range of disciplines, such as Antibacterial resistance and Colonization. His research in Carbapenem intersects with topics in Citrobacter amalonaticus, Pulsed-field gel electrophoresis, Citrobacter koseri, Citrobacter and Citrobacter braakii.
Jesús Oteo mainly focuses on Microbiology, Klebsiella pneumoniae, Multilocus sequence typing, Carbapenem and Public health. His Microbiology research is multidisciplinary, relying on both Molecular epidemiology, Enterobacteriaceae and Sequence analysis. His Klebsiella pneumoniae study integrates concerns from other disciplines, such as Pediatrics and Outbreak.
The study incorporates disciplines such as Population structure, Susceptible individual and Cefotaxime in addition to Multilocus sequence typing. His Carbapenem study deals with Escherichia coli intersecting with Typing, Imipenem, Meropenem and Infection control. As a part of the same scientific family, he mostly works in the field of Public health, focusing on Asymptomatic and, on occasion, Young adult.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
Marina Pollán;Beatriz Pérez-Gómez;Roberto Pastor-Barriuso;Jesús Oteo.
The Lancet (2020)
Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study.
Hajo Grundmann;Hajo Grundmann;Corinna Glasner;Corinna Glasner;Barbara Albiger;David M Aanensen;David M Aanensen.
Lancet Infectious Diseases (2017)
Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact.
Jesús Oteo;María Pérez-Vázquez;José Campos.
Current Opinion in Infectious Diseases (2010)
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.
Alberto M Borobia;Antonio J Carcas;Mayte Pérez-Olmeda;Luis Castaño.
The Lancet (2021)
Spread of Escherichia coli Strains with High-Level Cefotaxime and Ceftazidime Resistance between the Community, Long-Term Care Facilities, and Hospital Institutions
Jesús Oteo;Carmen Navarro;Emilia Cercenado;Alberto Delgado-Iribarren.
Journal of Clinical Microbiology (2006)
Extended-spectrum β-lactamase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2
Jesús Oteo;Karol Diestra;Carlos Juan;Verónica Bautista.
International Journal of Antimicrobial Agents (2009)
Antimicrobial-resistant Invasive Escherichia coli, Spain
Jesús Oteo;Edurne Lázaro;Francisco J. de Abajo;Fernando Baquero.
Emerging Infectious Diseases (2005)
Emergence of imipenem resistance in clinical Escherichia coli during therapy.
Jesús Oteo;Alberto Delgado-Iribarren;Dolores Vega;Verónica Bautista.
International Journal of Antimicrobial Agents (2008)
Emergence of OXA-48-producing Klebsiella pneumoniae and the novel carbapenemases OXA-244 and OXA-245 in Spain
Jesús Oteo;Juan Manuel Hernández;Mateu Espasa;Ana Fleites.
Journal of Antimicrobial Chemotherapy (2013)
Carbapenemase-Producing Enterobacteriaceae in Spain in 2012
Jesús Oteo;David Saez;Veronica Bautista;Sara Fernandez-Romero.
Antimicrobial Agents and Chemotherapy (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: